Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial

What Was Tested

This randomized controlled trial paper looks at Teriparatide.

The researchers compared combination treatment with teriparatide plus raloxifene with teriparatide alone in women with postmenopausal osteoporosis in a 6-month double-blind, placebo-controlled trial that measured biochemical markers of bone turnover and BMD.

The effects of combining two approved treatments for osteoporosis with different modes of action were examined by comparing teriparatide [rhPTH(1-34)] monotherapy with combination teriparatide and raloxifene therapy.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults, older adults and people over 80, women only.

A 6-month randomized, double-blind trial comparing teriparatide plus raloxifene (n = 69) versus teriparatide plus placebo (n = 68) was conducted in postmenopausal women with osteoporosis.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Teriparatide group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Teriparatide, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Teriparatide could be set against what happens without it.

What Was Measured

The researchers compared combination treatment with teriparatide plus raloxifene with teriparatide alone in women with postmenopausal osteoporosis in a 6-month double-blind, placebo-controlled trial that measured biochemical markers of bone turnover and BMD.

PubMed files the paper under topics including Bone Density, Calcium, Collagen, Collagen Type I, Creatine, Kidney Function Tests and Osteoporosis, Postmenopausal.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Teriparatide.

Its findings take up roughly 12 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2005 (Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research), a journal based in England.

More context: the Teriparatide compound page, all human trials.